US medtech, biotech companies still concerned with revised patent reform bill
This article was originally published in RAJ Devices
Executive Summary
Legislation to reform US patent law has been revised and reintroduced in the House of Representatives and the Senate1,2. The Patent Reform Act of 2009 continues to draw stiff opposition from the medtech, biotech and pharmaceutical industry associations, despite attempts by lawmakers to address their concerns and make improvements to the previous version of the act that was introduced in the previous Congress.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.